Pharmaceutical Biotechnology

2021 ◽  
2020 ◽  
Vol 21 (2) ◽  
pp. 97-109 ◽  
Author(s):  
Ana P. dos Santos ◽  
Tamara G. de Araújo ◽  
Gandhi Rádis-Baptista

Venom-derived peptides display diverse biological and pharmacological activities, making them useful in drug discovery platforms and for a wide range of applications in medicine and pharmaceutical biotechnology. Due to their target specificities, venom peptides have the potential to be developed into biopharmaceuticals to treat various health conditions such as diabetes mellitus, hypertension, and chronic pain. Despite the high potential for drug development, several limitations preclude the direct use of peptides as therapeutics and hamper the process of converting venom peptides into pharmaceuticals. These limitations include, for instance, chemical instability, poor oral absorption, short halflife, and off-target cytotoxicity. One strategy to overcome these disadvantages relies on the formulation of bioactive peptides with nanocarriers. A range of biocompatible materials are now available that can serve as nanocarriers and can improve the bioavailability of therapeutic and venom-derived peptides for clinical and diagnostic application. Examples of isolated venom peptides and crude animal venoms that have been encapsulated and formulated with different types of nanomaterials with promising results are increasingly reported. Based on the current data, a wealth of information can be collected regarding the utilization of nanocarriers to encapsulate venom peptides and render them bioavailable for pharmaceutical use. Overall, nanomaterials arise as essential components in the preparation of biopharmaceuticals that are based on biological and pharmacological active venom-derived peptides.


Author(s):  
Blaine A. Pfeifer ◽  
Guojian Zhang ◽  
Dehai Li

2017 ◽  
Vol 48 ◽  
pp. 258-259 ◽  
Author(s):  
Tiangang Liu ◽  
Chu-Young Kim

2021 ◽  
Vol 11 (3) ◽  
pp. 253-257
Author(s):  
Arindam Chakraborty ◽  
Dipak Kumar Singha ◽  
Manas Chakraborty ◽  
Payel Mukherjee

Therapeutic protein are one of the prime option of biologicals as per their clinical uses. In recent times, uses of therapeutic protein increases day by day. Protein therapeutics are used extensively to treat various diseases like cancer, AIDS etc. Due to recent advancement in pharmaceutical biotechnology the interest towards therapeutic proteins are augmenting nowadays. Various clinical research are going on in this field to treat different diseases and pharmaceutical industries are also make interest on therapeutic proteins. Among the various treatment options therapeutic protein will provide highest chance of clinical success. Some recent clinical trials demonstrate that therapeutic protein may provide the safe and potential option to treat various diseases, but there are some drawbacks also like some immunogenic issues, safety, stability problem of protein, degradation of protein in various conditions.


Author(s):  
Marion E. Glick

Public relations is not just sending out a press release or invitations to an event. It is the profession of managing communications between an organization and its audiences. As a public relations professional, you develop and execute communications programs that consider and support such corporate goals as reputation, the selling of products or services, recruitment of employees, or encouragement of investments. You can do this as an in-house professional at the company or as a client service if you work in an agency. If you want to apply your science journalism skills to corporate public relations, they will be highly prized by pharmaceutical, biotechnology, medical device, technology, and related companies. You not only comprehend the facts about environmental, physical, or life sciences, you can make them understandable to others. You can accurately and efficiently translate the function and value of a product or service to audiences as varied as customers, stockholders, regulators, and journalists, all of whom have different levels of scientific understanding. But being savvy about the scientific process and journalism is not enough. You also have to understand the business. Yes, it is about the money or, rather, commercial decision-making. To do your job well, you must know how the company makes money, who runs the show, who are the customers, how the business will grow, how it is regulated, and who are the existing or potential partners and competitors. And you should know these aspects as well as you know the company's research and development pipeline, patents, or marketed products or services. As someone who made the transition from managing public relations about medical research for academic and governmental organizations to that of Pharmaceuticals and biotechs, I can say that mastering “the business stuff” is possible. Many excellent resources are available, but start by skimming business magazines, checking out Hoover's Online (www.hoovers.com), and reading the annual reports of your company or clients. To manage corporate public relations, you need a program, which is the blueprint that captures the vision and the means to obtain it. Programs are very structured and have goals, objectives, strategies, and measurable tactics to achieve them.


Sign in / Sign up

Export Citation Format

Share Document